Simran Kaur
Family · Goodyear, AZNPI 1336432194
Payments from drug & device makers
Across 50 payments — averaging $19.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$172
- Sanofi$94
- Amgen$75
- Xeris Pharmaceuticals, Inc.$73
- Mannkind Corporation$52
- Lilly USA, LLC$51
- plus $473 from 19 others
What the payments were for
- Food & beverage$989100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 7 | $172 |
| Sanofi | 4 | $94 |
| Amgen | 3 | $75 |
| Xeris Pharmaceuticals, Inc. | 4 | $73 |
| Mannkind Corporation | 3 | $52 |
| Lilly USA, LLC | 3 | $51 |
| Novartis | 3 | $50 |
| Optinose US, Inc. | 2 | $47 |
| AbbVie | 2 | $45 |
| Novo Nordisk | 2 | $40 |
| Tandem Diabetes Care, Inc. | 2 | $34 |
| Bayer | 2 | $29 |
| Stryker | 1 | $25 |
| Verity Pharmaceuticals Inc. | 1 | $25 |
| Insulet Corporation | 1 | $23 |
| Acella Pharmaceuticals, LLC | 1 | $20 |
| AstraZeneca | 1 | $19 |
| Phadia US Inc. | 1 | $17 |
| Tolmar, Inc. | 1 | $15 |
| Corcept Therapeutics | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| GSK | 1 | $13 |
How this compares
$989 in reported general payments places this provider in the 65th percentile of 4,119 family providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 41 | $67,679 |
| OzempicSemaglutide | 49 | $63,856 |
| JardianceEmpagliflozin | 38 | $43,735 |
| FarxigaDapagliflozin Propanediol | 13 | $11,619 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $5,917 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $5,681 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 19 | $3,245 |
| SynthroidLevothyroxine Sodium | 16 | $1,742 |
| Levothyroxine Sodium | 62 | $926 |
| Metformin Hcl ErMetformin Hcl | 18 | $277 |
| Metformin Hcl | 42 | $222 |
| Atorvastatin Calcium | 11 | $135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $51 | $67,67941 claims |
| Novo NordiskOzempic | $40 | $63,85649 claims |
| AstraZenecaFarxiga | $19 | $11,61913 claims |
| AbbVieSynthroid | $45 | $1,74216 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $92662 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,119 family providers in Arizona.
Other family in Goodyear
- Sharon MagalonaMesa$449K
- Angela GoldenMunds Park$378K
- Kimberly HallaPhoenix$332K
- Kaitlyn LouchheimScottsdale$208K
- Rebecca McCollaumMesa$149K
- Susan SarabiaSun City West$114K
- Lindsay CarterTucson$108K
- Audrey StevensonPhoenix$83K
- Keith MorsePrescott$83K
- Celeste FineGilbert$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.